NPAL1 Inhibitors
NPAL1 inhibitors are a class of chemical compounds designed to interact with a specific biological target known as NPAL1, which stands for Neural Precursor cell Expressed, Developmentally Down-regulated 8 (NEDD8)-Activating Enzyme Like 1. This target is implicated in a biochemical pathway relevant to the conjugation process of NEDD8, a small protein related to ubiquitin. Ubiquitin and NEDD8 are involved in a process where they get attached to other proteins to alter their function, location, or signaling, a process known as ubiquitination and neddylation, respectively. The role of NPAL1 is less clear than the more extensively studied enzymes in the ubiquitin-proteasome system, but it is understood that inhibiting NPAL1 affects the regulation of the proteins that are normally modified by NEDD8. This interference with the normal neddylation process can result in significant changes in cellular functions.
Chemically, NPAL1 inhibitors are diverse, reflecting the need for specificity and high binding affinity to the NPAL1 enzyme. Their design is often based on the structure of the enzyme's active site and involves complex interactions with the enzyme's catalytic components to prevent the transfer of the NEDD8 molecule. The molecular architecture of these inhibitors typically includes moieties that can mimic the transition state or the substrate itself, aiming to competitively block the enzyme's activity. NPAL1 inhibitors are also characterized by their selectivity, as the compounds are tailored to interact with NPAL1 without affecting other similar enzymes in the cell, which is crucial to minimize off-target effects.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of phosphatidylinositol 3-kinase (PI3K), LY294002 prevents the phosphorylation and activation of AKT. Since NPAL1 is downstream of PI3K/AKT signaling, inhibition of PI3K by LY294002 can lead to reduced activity of NPAL1 due to decreased AKT-mediated signaling events. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor, Wortmannin irreversibly inhibits PI3K which leads to a decreased activation of the AKT pathway. This results in a reduced activation of downstream proteins like NPAL1 that are regulated through AKT signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that binds to FKBP12 and the mTOR complex, Rapamycin inhibits mTORC1 signaling. This suppression of mTORC1 can downregulate proteins involved in the PI3K/AKT/mTOR pathway, potentially decreasing NPAL1 activity if NPAL1 is downstream of this pathway. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Specifically targets AKT and inhibits its activation and phosphorylation. As a result, the downstream effectors of the AKT pathway, potentially including NPAL1, will have reduced activity due to this direct inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK1/2, PD98059 prevents the activation of ERK1/2 by inhibiting their phosphorylation. If NPAL1 is influenced by the ERK/MAPK pathway, then its activity would be indirectly inhibited by this compound. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Also a MEK inhibitor, U0126 impairs the activation of the MAPK/ERK pathway, which could lead to a reduction in NPAL1 activity if it is regulated by this signaling cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound selectively inhibits p38 MAPK, which is involved in stress response pathways. If NPAL1 is modulated by stress-induced signaling involving p38 MAPK, inhibition by SB203580 would result in decreased NPAL1 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK (c-Jun N-terminal kinase), SP600125 would prevent activation of JNK signaling. If NPAL1 is a downstream target of the JNK pathway, its activity would be indirectly diminished by this compound. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $81.00 | 5 | |
By inhibiting dihydroorotate dehydrogenase and tyrosine kinases, Leflunomide can disrupt pyrimidine synthesis and signal transduction pathways, potentially leading to the decreased activity of NPAL1 if it relies on these biological processes. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $150.00 $349.00 | 15 | |
A selective inhibitor of Aurora kinase, ZM-447439 can prevent the phosphorylation of downstream targets involved in cell cycle progression. If NPAL1 is involved in cell cycle regulation mediated by Aurora kinase, this inhibitor would reduce its activity. | ||||||